The US Food and Drug Administration (FDA) has given approval for US-based ARUP’s AAV5 DetectCDx, a companion diagnostic tool that aids the selection of adult patients eligible for treatment with Roctavian, a new gene therapy developed by BioMarin Pharmaceutical.
Roctavian received contemporaneous FDA approval for the treatment of adults with severe haemophilia A without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AAV5 DetectCDx, developed by ARUP Laboratories and BioMarin, is the first companion diagnostic immunoassay for a gene therapy product to receive FDA approval. ARUP will act as the sole laboratory testing provider in the US.
X-linked Haemophilia A, also known as Classic Haemophilia or Factor VIII deficiency, is the most common clotting disorder. Missing or defective factor VIII (FVIII), a clotting protein, means that injured blood vessels cannot heal in the usual way, which can be painful and potentially life-threatening.
Roctavian uses AAV5 as a vector to deliver a functional copy of FVIII in a one-time infusion, which aims to reduce or eliminate the need for chronic prophylaxis treatment.
AAV5 DetectCDx will be used to determine whether the patient has anti-AAV5 antibodies, which may inhibit the efficacy of Roctavian. Only those without anti-AAV5 antibodies will be eligible for the gene therapy under FDA approval.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOn the collaboration between ARUP and US-based BioMarin, Emily Coonrod, the senior director of companion diagnostics in the PharmaDx department at ARUP Laboratories said: “It is extremely satisfying to see the effort and dedication of both teams come to fruition after a successful and long-standing collaboration, it has required the combined expertise, hard work, and perseverance of both teams to achieve this milestone.”
Adeno-associated Virus Vectors (AAV) detection kits are becoming more popular. In November 2022, PerkinElmer introduced AAV detection kits for gene therapy research.
According to a report by GlobalData, the global gene therapy market is expected to reach sales of $15.2 billion by 2028.
